<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> is associated with cerebral small vessel disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the relationship between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and 1) volumetric measure of white matter change (WMC), 2) silent brain <z:mpath ids='MPATH_124'>infarcts</z:mpath>, 3) <z:hpo ids='HP_0002059'>cerebral atrophy</z:hpo> on MRI and 4) cognition on a consecutive cohort of patients with <z:hpo ids='HP_0001297'>stroke</z:hpo> associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>SUBJECTS AND METHODS: Fifty-seven patients consecutively admitted to the <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0001297'>Stroke</z:hpo> Unit in a university hospital due to <z:hpo ids='HP_0001297'>stroke</z:hpo> associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> were recruited and assessed three months after the <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Non-fasting <z:chebi fb="0" ids="17230">homocysteine</z:chebi> was obtained </plain></SENT>
<SENT sid="4" pm="."><plain>Using MRI, the number of <z:mpath ids='MPATH_124'>infarcts</z:mpath>, volume of WMC and <z:hpo ids='HP_0002059'>cerebral atrophy</z:hpo> were measured </plain></SENT>
<SENT sid="5" pm="."><plain>General cognitive functions were assessed using the Mini Mental State Examination and <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> Assessment Scale </plain></SENT>
<SENT sid="6" pm="."><plain>Mattis <z:hpo ids='HP_0000726'>Dementia</z:hpo> Rating Scale - Initiation/<z:e sem="disease" ids="C0233651" disease_type="Mental or Behavioral Dysfunction" abbrv="">Perseveration</z:e> subset was used to assess executive cognitive functions </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> (&gt; or = 14.88 micromol/L) significantly accounted for the volume of WMC on MRI in a multivariate stepwise regression model (adjusted R(2)=0.058, p &lt;0.05) after adjustment for age and <z:chebi fb="3" ids="37445">folate</z:chebi> level </plain></SENT>
<SENT sid="8" pm="."><plain>Patients in the highest quartile of WMC volume had significantly higher levels of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> than those in lowest quartile (p &lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>No significant relationship was found between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and silent brain <z:mpath ids='MPATH_124'>infarcts</z:mpath>, <z:hpo ids='HP_0002059'>cerebral atrophy</z:hpo> and performance on psychometric tests </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> is associated with volumetric measure of WMC among patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The role of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> in the development of silent brain <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0002059'>cerebral atrophy</z:hpo> as previously reported cannot be ascertained in this study </plain></SENT>
<SENT sid="12" pm="."><plain>No direct relationship was found between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and cognitive functions </plain></SENT>
</text></document>